Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
53%
Chemotherapy
44%
Lung Cancer
37%
Overall Survival
34%
Immune Checkpoint Inhibitor
31%
Neoplasm
28%
Progression Free Survival
27%
Chemoradiation Therapy
21%
Osimertinib
20%
Chronic Graft Versus Host Disease
19%
Malignant Neoplasm
18%
Epidermal Growth Factor Receptor Kinase Inhibitor
17%
Protein Tyrosine Kinase Inhibitor
17%
Adverse Event
16%
Diffuse Large B Cell Lymphoma
16%
Lung Adenocarcinoma
14%
Disease
14%
Cisplatin
13%
Acute Myeloid Leukemia
13%
Survival Rate
13%
Anaplastic Lymphoma Kinase
12%
Rituximab
11%
Remission
11%
Pembrolizumab
11%
Infection
10%
Gilteritinib
10%
Promyelocytic Leukemia
10%
Oral Mucositis
10%
Docetaxel
10%
Programmed Cell Death
10%
Afatinib
9%
Acute Lymphoblastic Leukemia
9%
Blinatumomab
9%
Monotherapy
9%
Cyclophosphamide
9%
Graft Versus Host Reaction
9%
Radiation Pneumonia
9%
Tamibarotene
8%
NK T Cell Lymphoma
8%
Combination Therapy
8%
Acute Graft Versus Host Disease
8%
Retinoic Acid
7%
Leukemia
7%
Pleura Effusion
7%
Mouse
7%
Bevacizumab
7%
Recurrence Free Survival
6%
Asparaginase
6%
Pralatrexate
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
79%
Neoplasm
42%
Allogeneic Hematopoietic Stem Cell Transplantation
31%
Epidermal Growth Factor Receptor
30%
Immune Checkpoint Inhibitor
27%
Diffuse Large B-Cell Lymphoma
25%
Lung Cancer
24%
Acute Myeloid Leukemia
24%
Lung Adenocarcinoma
22%
Hematopoietic Stem Cell Transplantation
20%
Malignant Neoplasm
19%
NK T Cell Lymphoma
18%
Disease
18%
Overall Survival
17%
Chemoradiotherapy
16%
Progression Free Survival
15%
Cisplatin
14%
Programmed Cell Death
13%
Nivolumab
13%
Follicular Lymphoma
13%
Graft Versus Host Reaction
13%
Multivariate Analysis
12%
B Cell
12%
Pembrolizumab
11%
Survival Rate
11%
Exon
11%
Cytotoxic T-Cell
10%
MALT Lymphoma
10%
Docetaxel
10%
Radiation Therapy
9%
Blinatumomab
9%
Acute Promyelocytic Leukemia
9%
Biopsy
9%
Adverse Event
9%
Disease Exacerbation
9%
Peripheral T-Cell Lymphoma
9%
Lymphocyte
8%
Prognostic Factor
8%
Recurrent Disease
8%
Computer Assisted Tomography
8%
Arm
8%
Methotrexate
8%
Acute Graft Versus Host Disease
8%
Tyrosine-Kinase Inhibitor
8%
Leukemia
8%
Acute Lymphoblastic Leukemia
7%
Programmed Death-Ligand 1
7%
Bronchiolitis Obliterans
7%
Azacitidine
7%
Busulfan
7%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Immune Checkpoint Inhibitors
26%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
24%
Lung Cancer
24%
Non-small Cell Lung Cancer Patients
18%
Chemotherapy
16%
Okayama
16%
Epidermal Growth Factor Receptor
15%
Lung Adenocarcinoma
15%
EGFR mutation
14%
Progression-free Survival
14%
Programmed Death-ligand 1 (PD-L1)
13%
Graft-versus-host Disease (GvHD)
13%
Natural Killer T-cell Lymphoma
11%
Cancer Study
10%
Osimertinib
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Confidence Interval
10%
Bronchiolitis Obliterans
10%
Japan
9%
Retrospective Analysis
9%
Non-infectious Pulmonary Complication
9%
Stage III Non-small Cell Lung Cancer
9%
Post-transplantation Cyclophosphamide (PTCy)
9%
Phase II Study
9%
Cisplatin
9%
Re-biopsy
8%
Intrabony
8%
Nasal Type
8%
Extranodal
8%
Hematopoietic Stem Cell Transplantation
8%
Tumor
8%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
7%
T790M
7%
Overall Survival
7%
Relapsed or Refractory
7%
Gilteritinib
7%
Docetaxel
6%
Bevacizumab
6%
Immunochemotherapy
6%
Re-administration
6%
Emphysema
6%
Cell Collection
6%
Angioimmunoblastic T-cell Lymphoma
6%
Pralatrexate
6%
Marginal Zone Lymphoma
6%
Afatinib
6%
Poor Performance Status
6%
Forodesine
6%
